Mirae Asset Global Investments Co. Ltd. Acquires 19,204 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Mirae Asset Global Investments Co. Ltd. increased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 9.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 229,604 shares of the biopharmaceutical company’s stock after acquiring an additional 19,204 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Amicus Therapeutics were worth $3,258,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of FOLD. SkyView Investment Advisors LLC bought a new stake in Amicus Therapeutics during the 2nd quarter valued at about $66,000. Point72 Middle East FZE bought a new stake in Amicus Therapeutics during the 4th quarter valued at about $81,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Amicus Therapeutics by 97.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,368 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 3,638 shares during the period. Belpointe Asset Management LLC grew its stake in shares of Amicus Therapeutics by 1,013.1% in the first quarter. Belpointe Asset Management LLC now owns 9,172 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 8,348 shares during the period. Finally, Engineers Gate Manager LP bought a new stake in shares of Amicus Therapeutics in the third quarter worth approximately $106,000.

Analysts Set New Price Targets

FOLD has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $22.00 price target on shares of Amicus Therapeutics in a research note on Thursday, February 29th. JPMorgan Chase & Co. reduced their price target on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Monday, March 18th.

Amicus Therapeutics Stock Performance

FOLD opened at $10.55 on Thursday. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 2.42. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -20.69 and a beta of 0.75. The company’s 50 day moving average is $12.30 and its 200 day moving average is $12.02. Amicus Therapeutics, Inc. has a 12-month low of $9.70 and a 12-month high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. The firm had revenue of $115.08 million for the quarter, compared to analysts’ expectations of $115.11 million. On average, equities research analysts predict that Amicus Therapeutics, Inc. will post 0.01 EPS for the current year.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, Chairman John F. Crowley sold 55,327 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $12.36, for a total transaction of $683,841.72. Following the transaction, the chairman now owns 782,452 shares of the company’s stock, valued at $9,671,106.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Bradley L. Campbell sold 4,167 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $58,338.00. Following the sale, the chief executive officer now owns 871,219 shares in the company, valued at $12,197,066. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman John F. Crowley sold 55,327 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $12.36, for a total transaction of $683,841.72. Following the sale, the chairman now owns 782,452 shares in the company, valued at approximately $9,671,106.72. The disclosure for this sale can be found here. Insiders have sold 103,435 shares of company stock valued at $1,346,447 over the last 90 days. 2.10% of the stock is currently owned by corporate insiders.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.